Search results
Order by most recent / most popular / relevance
Results: 1-10 of 160
Data protection: defining innovative drug in Canada
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- April 22 2013
Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994
Celgene Corporation v Canada (AG) - Supreme Court of Canada grants leave to appeal
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
The Supreme Court of Canada has granted Celgene Corporation's application for leave to appeal the decision of a majority of the Federal Court of Appeal regarding the jurisdiction of the Patented Medicine Prices Review Board
Apotex v Sanofi, case management directions on the late disclosure of documents or information
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 21 2010
Prior to a case management conference within a streamlined case, the Prothonotary ordered the parties to make submissions at the conference on the question of whether a date should be set after which the parties required either consent of the other party or leave of the Court to serve a supplementary affidavit of documents or a corrected or completed information in answer to a discovery question
Apotex v. Canada (Minister of Health)
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- May 28 2009
Apotex brought a judicial review of the Minister’s refusal to issue a NOC regarding its version of aspirin
Sanofi-Aventis v Pharmascience; 55.2 proceeding; motion to limit NOA based on issue estoppel; October 17, 2007 - ramipril
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- October 25 2007
The innovator brought a motion seeking a determination that the generic was precluded from making further allegations of invalidity by the doctrines of abuse of process, res judicata andor issue estoppel, on the basis that the same generic company had made a previous allegation of invalidity that had been found to have no merit
PMPRB guidelines and reporting requirements in effect for 2010
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- January 22 2010
The Patented Medicine Prices Review Board (PMPRB) released new Guidelines in 2009, including the new pricing tests the Board will apply for patented medicines
Shire Biochem Inc. v. Canada; Janssen-Ortho Inc. v. Canada
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- December 20 2007
The Court reasoned that because the Patent Act defines the patentee as the person entitled to the benefit of the patent for that invention, and because the Patent Act provides the ability to sue for reasonable compensation from the time the patent application is laid open, once the patent is granted a patentee is entitled to the benefit of the patent from the date the patent application was laid open
Bayer v Sandoz; motion to strike pleadings; September 26, 2007 - ciprofloxacin
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- October 25 2007
The Court upheld the decision of a Prothonotary to strike portions of a Defendant's Defence and Counterclaim
Eli Lilly Canada and PMPRB reach agreement on the price of Forteo
- Gowling Lafleur Henderson LLP
- -
- Canada
- -
- July 10 2007
On July 6, 2007, the PMPRB announced that it has approved a Voluntary Compliance Undertaking by Eli Lilly Canada with respect to Forteo
Strategic risk management for biotechnology companies
- Gowling Lafleur Henderson LLP
- -
- Canada, Global
- -
- August 1 2008
Ernst & Young has released a report identifying the top 10 strategic risks facing biotechnology companies over the next 5 years
Current Search
- Workarea - Healthcare
- Workarea - Intellectual Property
- Firm Name - Gowling Lafleur Henderson LLP
- Jurisdiction - Canada
Suggested Facets
Author
- Adrienne Blanchard (3)
- Beverley Moore (49)
- Graham Ragan (4)
- Jane E. Clark (1)
- Jennifer Wilkie (4)
- Natalie de Paulsen (1)
- Patrick Stewart Smith (1)
- Scott Foster (10)
- Wendy Wagner (1)